We are pleased to announce that BIOPIX-T is participating as a design and commercialization partner, in a grant that was awarded to a consortium of 12 esteemed research institutions and companies, with the aim to develop a point-of-care device for the early detection of Sepsis.
The complete title of the proposal is “A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE” (AMBROSIA) and was awarded from an H2020-Research and Innovation Action, under the call of Digital and emerging technologies for competitiveness and fit for the green deal (HORIZON-CL4-2022-DIGITAL-EMERGING-01).
The project will be coordinated by the Aristoteleio Panepistimio Thessalonikis, Greece and the consortium will be comprised by, the University of Southampton form the UK, Ligentec from Switzerland, the Catalan Institute of Nanoscience and Nanotechnology from Spain, the University of Bourgogne from France, X-Celeprint from Ireland, the Vall d’Hebron Research Institute from Spain, Argotech from the Czech Republic, BIOPIX DNA TECHNOLOGY P.C. from Greece, microLIQUID from Spain, the University of Ioannina from Greece and SMART PHOTONICS BV from the Netherlands.
From the project’s abstract: Sepsis is a life-threatening whole-body inflammatory reaction caused by a severe infection (e.g., bacteria, virus). With mortality rates around 35%, sepsis is responsible for 11 million deaths worldwide every year, being the largest killer of children (more than 5 million annually) . Furthermore, sepsis survivors commonly suffer long-term health damage with a diminished quality of life and persistent high risk of mortality. In economic terms, sepsis represents a primary cost of hospitalization in developed regions, expending up to $24 billion/year in the US or €9 billion/year in Germany , . The window of opportunity for sepsis management is in hours: the chance of survival drops by 7.6% each hour of disease progression until an appropriate treatment is started . Early and accurate sepsis detection and stratification is essential for enhancing survival rates. This is challenging, due to: i) complex diagnostic criteria requiring multiple screenings for differential diagnosis, (ii) time-consuming methods for identifying the bacterial causes of sepsis. Even worse, these conventional immunoassay techniques are performed in centralized laboratories, causing extra delays due to specimen transfers. Point-of-care (PoC) sepsis testing can perform the analysis at bedside, enabling earlier diagnosis and facilitating therapy assessment.
Dr. Alexandros Pantazis, Co-founder and Head of Production of BIOPIX-T said: “We are looking forward to working with our esteemed consortium partners on this interesting and of high impact project. Our participation will enhance our brand awareness in this space and will allow us to showcase the unique abilities of BIOPIX-T to design, manufacture and commercialize medical diagnostic devices for the point of care”.
BIOPIX DNA TECHNOLOGY P.C. (https://biopix-t.com) is a dynamic molecular diagnostics startup founded in 2019 with a mission to offer affordable systems for the point-of-care testing to every potential user and a vision to become an international leader in the field of molecular diagnostics. BIOPIX-T is fully licensed and certified as a Designer and Manufacturer of medical devices (ISO13485) and its products have received the pan-European free sales certificate (CE IVD). The company targets two healthcare-diagnostics related markets through the production of standardized assays for detection and monitoring of Infectious Diseases and Companion Diagnostics.
 J. Vincent et. al, Critical Care vol. 23, no. 1, pp. 196, 2019, doi: 10.1186/s13054-019-2478-6.
 A. B. Martin et. al., Health Aff., vol. 35, no. 1, pp. 150–160, 2016, doi: 10.1377/hlthaff.2015.1194.
 E. S. R. 2021 (https://www.europeansepsisalliance.org/
 A. Kumar et al., Crit. Care Med., vol. 34, no. 6, pp. 1589–1596, 2006, doi: 10.1097/01.CCM.0000217961.75225.E9.